Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RADX with free AI briefings, catalyst countdowns, and dilution alerts.

RADX · Radiopharm Theranostics Ltd

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4.1M Cash on Hand
0.9mo Cash Runway
Follow RADX by email Get an email when RADX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RADX, unsubscribe in one click. Privacy

📣 What RADX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
161Tb RAD402 Castration-resistant Prostate Cancer Phase 1/2 · NCT07259213 Recruiting
Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal… Castration-Resistant Prostate Cancer (CRPC) Phase 1/2 · NCT07189871 Recruiting
BetaBart + unlabeled BetaBart Castration-Resistant Prostate Cancer (CRPC) Phase 1/2 · NCT07189871 Recruiting
RAD101 (18F-FPIA) Brain Metastases From Solid Tumors Phase 2 · NCT06777433 Active not recruiting
Lutetium Lu 177-DOTA-DUNP19 LNTH2403 Imaging Phase 1 · NCT07272642 Not yet recruiting
Gallium Ga 68 Relitegatide Brexetan Healthy Volunteers Phase 1 · NCT05799274 Active not recruiting
177Lu-RAD202 HER2 Gene Mutation Early Phase 1 · NCT06824155 Recruiting
Lutetium Lu 177 Anti-PD-L1 Nanobody RAD204 PDL1 Gene Mutation Early Phase 1 · NCT06305962 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RADX holds $4.1M in cash and short-term investments and burns about $13.2M/quarter from operations, an estimated runway of 0.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 84 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RADX files for a raise →

👥 Who Owns RADX

Insiders 5.1% Other 5%+ holders 22.4% Institutions 16.7% Public and other holders 55.8%
HolderTypeShares% of sharesAs of
Lantheus Omega, LLC 5%+ holder (13G) 792,958,513 22.37% 2026-07-28
Regal Partners Holdings Pty Limited Institution (13G, 5%+) 320,694,680 9.05% 2025-12-31
Morgan Stanley Institution (13G, 5%+) 272,558,527 7.69% 2026-09-30
Paul Hopper
Director
Insider 147,721,428 4.17% 2026-03-18
Riccardo Canevari
Managing Director and CEO, Director
Insider 22,679,986 0.64% 2026-03-18
Ian Lawrence Turner
Director
Insider 9,985,292 0.28% 2026-03-18
Hester Denise Larkin
Director
Insider 644,247 0.02% 2026-03-18
Aaron James Laurita
Chief Financial Officer
Insider 26,357 0.00% 2026-03-18

Share count 3,544,216,160 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RADX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RADX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.